External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Reported revenue grew by 35.3% YoY and was majorly contributed by Biosimilars (+53.5% YoY) and generics (+18.1% YoY).</li><li>Adj. PAT of Rs 251 Cr increased by 14.2% YoY after adjusting one-time costs of Rs 271 Cr which arose due to the Viatris deal.</li><li>Existing and new products (bAdalimumab, bBevacizumab, bAspart) in Europe and Emerging Markets added growth in the last quarter.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Reported revenue grew by 35.3% YoY and was majorly contributed by Biosimilars (+53.5% YoY) and generics (+18.1% YoY).Adj. PAT of Rs 251 Cr increased by 14.2% YoY after adjusting one-time costs of Rs 271 Cr which arose due to the Viatris deal.Existing and new products (bAdalimumab, bBevacizumab, bAspart) in Europe and Emerging Markets added growth in the last quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon Ltd - Aggressive Capital Allocation Led to Suppressed Return Ratios

Thematic (Sector/Industry)

<div><div><div><div><ul><li>In Q3FY23, the Pharma sector is expected to benefit from positive attributes such as currency depreciation, fall in raw material prices, low crude prices, and correction in shipping prices which would aid in revenue growth and improvement in gross margins.</li><li>We expect the Pharma universe under our coverage to report healthy aggregate Revenue/EBITDA/PAT growth of 7.4%/9.5%/9.1% YoY. 8% depreciation in the Indian currency (Rs) may majorly contribute to the overall growth of 7.4% for the last quarter.</li><li>Low single-digit growth in the US market (due to intense competition) and low double-digit growth in the India business after Covid-19 business has now stabilised. </li></ul></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

In Q3FY23, the Pharma sector is expected to benefit from positive attributes such as currency depreciation, fall in raw material prices, low crude prices, and correction in shipping prices which would aid in revenue growth and improvement in gross margins.We expect the Pharma universe under our coverage to report healthy aggregate Revenue/EBITDA/PAT growth of 7.4%/9.5%/9.1% YoY. 8% depreciation in the Indian currency (Rs) may majorly contribute to the overall growth of 7.4% for the last quarter.Low single-digit growth in the US market (due to intense competition) and low double-digit growth in the India business after Covid-19 business has now stabilised. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).</li><li>Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.34 billion.</li><li>Biocon Biologics entered into a strategic alliance with SILS for access to 100 million vaccine doses per annum for 15 years.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.34 billion.Biocon Biologics entered into a strategic alliance with SILS for access to 100 million vaccine doses per annum for 15 years.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon - Steady Performance; Focus on Viatris Integration...

Biocon - Steady Performance; Focus on Viatris Integration

Biocon Ltd (BIOCON) - Steady Performance; Focus on Viatris Integration...

India

Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocon Ltd (BIOS IN)

Biocon Ltd - Aggressive Capital Allocation Led to Suppressed Return Ratios

Existing and new products (bAdalimumab, bBevacizumab, bAspart) in Europe and Emerging Markets added growth in the last quarter.

Axis Direct

Pharma - Q3FY23 - Earnings Preview

Low single-digit growth in the US market (due to intense competition) and low double-digit growth in the India business after Covid-19 business has...

Axis Direct

Biocon - Steady Performance; Focus on Viatris Integration...

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).

ICICI Securities Limited

Biocon - Steady Performance; Focus on Viatris Integration

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).

ICICI Securities Limited

Biocon Ltd (BIOCON) - Steady Performance; Focus on Viatris Integration...

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).

ICICI Securities Limited

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)